These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 37554322)

  • 1. Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy.
    Lv Z; Luo F; Chu Y
    Front Immunol; 2023; 14():1199145. PubMed ID: 37554322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review.
    Tang C; Zhang Y
    Pathol Res Pract; 2024 Oct; 262():155518. PubMed ID: 39146830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paths and challenges of "off-the-shelf" CAR-T cell therapy: An overview of clinical trials.
    Moradi V; Omidkhoda A; Ahmadbeigi N
    Biomed Pharmacother; 2023 Dec; 169():115888. PubMed ID: 37979380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic "Off-the-Shelf" CAR T cells: Challenges and advances.
    Chen S; van den Brink MRM
    Best Pract Res Clin Haematol; 2024 Sep; 37(3):101566. PubMed ID: 39396256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
    Zhao Q; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
    An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
    Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Off-the-shelf' allogeneic CAR T cells: development and challenges.
    Depil S; Duchateau P; Grupp SA; Mufti G; Poirot L
    Nat Rev Drug Discov; 2020 Mar; 19(3):185-199. PubMed ID: 31900462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma.
    Martínez Bedoya D; Dutoit V; Migliorini D
    Front Immunol; 2021; 12():640082. PubMed ID: 33746981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma.
    Khurana A; Lin Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):171-187. PubMed ID: 35212892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?
    Watanabe N; Mamonkin M
    Cancer J; 2021 Mar-Apr 01; 27(2):176-181. PubMed ID: 33750078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches to develop "off-the-shelf" chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review.
    Aparicio C; Acebal C; González-Vallinas M
    Exp Hematol Oncol; 2023 Aug; 12(1):73. PubMed ID: 37605218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
    Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
    Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis.
    Chen S; Zhang Y; Fang C; Zhang N; Wang Y; Chen R; Li Y; Tu S
    Crit Rev Oncol Hematol; 2022 Nov; 179():103807. PubMed ID: 36087853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials.
    Smirnov S; Petukhov A; Levchuk K; Kulemzin S; Staliarova A; Lepik K; Shuvalov O; Zaritskey A; Daks A; Fedorova O
    Front Immunol; 2021; 12():780145. PubMed ID: 34975869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy.
    Wang Y; Wang L; Seo N; Okumura S; Hayashi T; Akahori Y; Fujiwara H; Amaishi Y; Okamoto S; Mineno J; Tanaka Y; Kato T; Shiku H
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies.
    Dhakal B; Chhabra S; Savani BN; Hamadani M
    Br J Haematol; 2022 Apr; 197(1):28-40. PubMed ID: 34671973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.